 NEW YORK, Sept. 27, 2022 GLOBE NEWSWIRE -- IN8bio, Inc. Nasdaq: INAB, a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced that William Ho, IN8bios Chief Executive Officer, will be a speaker on the Cell Therapy in Solid Tumors panel at the Cantor Oncology HemOnc Conference. The panel will take place at 1:45 p.m. ET on September 28, 2022. 